Frontpage Hero

Because we care, we need to act

Read more here
Annual and Sustainability Report

2017 Annual and Sustainability Report

"We have successfully launched our next-generation haemophilia products Elocta and Alprolix, and established a good position for them both in our main markets. Our track record of very strong quarter-on-quarter growth shows that we have managed to deliver consistently on our launch strategy. In the Annual Report, we have outlined how this growth will fuel our strategy to become global leaders in rare diseases, building on our capabilities and strengths within the field", says Guido Oelkers, CEO.
Click here to go to the on-line version

Annual General Meeting 2018

The Annual General Meeting was held on Wednesday, May 9, 2018 at 15:00 at Näringslivets Hus, Storgatan 19, Stockholm, Sweden.
More information about the AGM is found here.
Sobi Annual General Meeting

Press releases

Data presented at ASH support emapalumab as an innovative, targeted therapeutic option for primary HLH

Swedish Orphan Biovitrum AB (publ) (Sobi™) and Novimmune SA are presenting data from the pivotal phase 2/3 clinical study of emapalumab-lzsg in primary haemophagocytic lymphohistiocytosis (HLH) as part of the late-breaking abstract session at the 60th Annual Meeting of...

12/04/2018 - 01:30
At ASH, extended half-life therapies Elocta® and Alprolix® demonstrate proven efficacy and well-characterised safety over four years

ASPIRE and B-YOND extension studies show no inhibitor development and consistently low annualised bleeding rates in study participants over four years with Elocta and Alprolix, respectively.

Swedish Orphan Biovitrum AB (publ) (Sobi™) and Bioverativ Inc., a Sanofi...

12/01/2018 - 17:00
Late-breaking abstract at ASH supports evidence on transformative first-ever treatment in primary HLH

Swedish Orphan Biovitrum AB (publ) (Sobi™) and Novimmune SA are pleased to announce that the abstract “Safety and efficacy of emapalumab in paediatric patients with primary hemophagocytic lymphohistiocytosis” was accepted as a late-breaking abstract at the 60th Annual...

11/22/2018 - 13:00
FDA approves Gamifant® (emapalumab), the first and only treatment for primary haemophagocytic lymphohistiocytosis (HLH)

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI), an international biopharmaceutical company dedicated to rare diseases, and Novimmune SA, a Swiss biotech company, today announce that the US Food and Drug Administration (FDA) has approved Gamifant® (emapalumab...

11/20/2018 - 15:29
Read more
Contact us

Sobi Head Office

info@sobi.com
+46 8 697 20 00
Tomtebodavägen 23A
SE-112 76 Stockholm, Sweden
All contacts